A 52-year-old woman with an intact uterus wants systemic estrogen for hot flashes. What must be added and why?
Choose an answer, then check it.
Clinical Pharmacology · Reproductive Medications
Menopause Hormone Therapy
On this page 6 sections
In 30 seconds
Menopause hormone therapy (MHT) replaces the estrogen the ovaries stop making, relieving hot flashes, night sweats, sleep disruption, and vaginal dryness while slowing bone loss. Estrogen is the most effective treatment for vasomotor symptoms, but a woman with an intact uterus must take a progestogen alongside it to prevent uterine cancer. Route matters: patches and gels carry lower clotting risk than oral pills. Because trials linked long-term combined therapy to clot, stroke, and breast cancer risk, current practice favors the lowest effective dose for the shortest reasonable time, started close to menopause.
The college version
The physiology being treated
As the ovaries run out of responsive follicles, estrogen falls sharply. The hypothalamus loses estrogen's feedback and its temperature center destabilizes, producing hot flashes and night sweats (vasomotor symptoms). Falling estrogen also thins and dries vaginal and urinary tissue, producing genitourinary syndrome of menopause (dryness, irritation, painful intercourse, urinary urgency). Sleep fragments, partly from night sweats and partly from direct effects on sleep architecture. Bone loss accelerates because estrogen normally restrains osteoclasts, so resorption outpaces formation and fracture risk climbs. A woman in her late forties who begins skipping periods, waking drenched in sweat, and struggling to fall back asleep is living this cascade.
Systemic estrogen and the progestogen rule
Systemic estrogen (oral, patch, or gel) is the most effective therapy for vasomotor symptoms and also helps bone density and genitourinary symptoms. The essential rule: unopposed estrogen stimulates the endometrial lining and can drive hyperplasia and cancer, so any woman with an intact uterus must take a progestogen along with estrogen, continuously or cyclically. A woman past hysterectomy has no endometrium to protect and can use estrogen alone.
Routes of delivery
Oral estrogen passes through the liver first, boosting clotting factors and triglycerides more than other routes and raising thromboembolism risk. Transdermal patches and gels bypass that hepatic pass, carrying lower thrombotic risk, and are often preferred in women with metabolic risk factors. For genitourinary symptoms alone, low-dose vaginal estrogen (cream, tablet, or ring) treats local tissue with minimal systemic absorption, needing no added progestogen even with an intact uterus, and can often be used when systemic estrogen is contraindicated.
Non-hormonal alternatives
Options for women who cannot or prefer not to use hormones include certain SSRIs and SNRIs, gabapentin, and the newer neurokinin-3 receptor antagonists, which block a hypothalamic hot-flash pathway. These do not address bone loss or genitourinary atrophy as well as estrogen.
Risk picture and the timing hypothesis
Trial data, most famously the Women's Health Initiative, showed combined estrogen-progestogen therapy, especially started well past menopause, carried increased risk of thromboembolism, stroke, gallbladder disease, and breast cancer with extended use. Later reanalysis introduced the "timing hypothesis": starting close to the menopause transition, in younger women, is more favorable than starting a decade or more later, partly because vascular tissue ages and responds differently to estrogen.
Contraindications and principles of use
MHT is avoided in estrogen-dependent cancers, unexplained vaginal bleeding, active or prior thromboembolism, active liver disease, and coronary or cerebrovascular disease. The guiding principle is the lowest effective exposure for the shortest duration, with periodic reassessment. An exception is premature ovarian insufficiency, where the ovaries fail well before typical age; replacement is recommended until the usual age of menopause, restoring hormone levels the body would otherwise still produce.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of estrogen like a thermostat setting your body relies on for years. When the ovaries stop making it, the thermostat gets glitchy, causing heat waves, sweaty nights, and trouble sleeping. Hormone therapy is like putting a fresh battery back in. But there's a rule: if someone still has their uterus, estrogen alone can make its lining overgrow unhealthily, so doctors add a second hormone, progestogen, to keep things balanced. If the uterus was already removed, that second hormone isn't needed.
How you get the hormone matters too. A pill passes through the liver first, stirring up clotting risk, while a patch or gel soaks in directly, which is gentler. Non-hormone medicines can calm heat waves without using estrogen at all. Starting soon after the ovaries slow down seems safer than starting years later, so doctors aim for the smallest helpful amount for the shortest sensible time, checking back regularly.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A woman had a hysterectomy five years ago and now wants estrogen for vasomotor symptoms. Does she need a progestogen added, and why or why not?
Show answer
No, because a hysterectomy removed the uterus, leaving no endometrial lining for unopposed estrogen to overstimulate.
Progestogen exists only to protect that lining, so without a uterus estrogen alone is appropriate.
A 29-year-old is diagnosed with premature ovarian insufficiency. Explain why hormone replacement is recommended for her differently than for a typical 55-year-old considering MHT.
Show answer
Her ovaries stopped decades early, so replacing hormones until the typical menopause age restores what her body would still naturally produce, protecting bone and cardiovascular health.
A 55-year-old replaces hormones already stopped on a normal schedule, unlike a 29-year-old who would otherwise lack estrogen for decades before naturally needing it.
Quick check
3 questions here. Answers stay hidden until you check.
Why does transdermal estrogen carry lower thrombotic risk than oral estrogen?
Choose an answer, then check it.
Which best describes the "timing hypothesis" from reanalysis of WHI data?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.